Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Our Policies

Our Policies (Quality, HSEE, Human Resources, Innovation & Entrepreneurship) communicate and document our values.

Page
Read more

Speak Up!

An Ethics Line to enable team members to Speak Up!

Page
Read more

Our experts content

We invite you to read, listen and learn with our experts content.

Page
Read more